| Bioactivity | S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer drug resistance[1]. |
| Target | IC50: 2.88 ± 1.10 μM (AKR1C1), 0.13 ± 0.03 μM (AKR1C3), 0.75 ± 0.32 μM (AKR1C4) |
| Name | S07-2005 (racemic) |
| CAS | 1826337-40-9 |
| Formula | C20H23NO6 |
| Molar Mass | 373.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Siyu He, et al. Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Med. Chem. Lett. Jun 2022. |
S07-2005 (racemic)
CAS: 1826337-40-9 F: C20H23NO6 W: 373.40
S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.